Project Grant R21AI144386

Novobiotic Pharmaceuticals, LLC received a $4.5 million Project Grant award from the Defense Health Agency to conduct late-stage preclinical development of the antibiotic teixobactin through April 2026. The funding supports research under the Military Medical Research and Development program, which aims to develop medical solutions for battlefield injuries and infectious diseases. Specifically, the award will allow Novobiotic to advance teixobactin, initially discovered using its iChip...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 aims to develop a platform for detecting genetic antibiotic resistance motifs that can predict current and future susceptibility to therapeutics. The project will establish the feasibility of leveraging mutational signatures in bacterial DNA to identify antibiotic resistance status, including the potential for rapid development of multi-drug resistance. This approach...

This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000.00 to Resonantia Diagnostics, Inc. to develop a transformative diagnostic platform for rapid identification and antimicrobial susceptibility testing of pathogens. The project aims to achieve three key technical objectives: (1) demonstrate accurate antimicrobial susceptibility testing at very low pathogen loads, (2) validate testing...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $299,163 to Phase Genomics Inc. for a proof-of-concept study to develop a novel antimicrobial approach using mRNA-based delivery of bacteriophage-derived endolysin proteins. The project aims to evaluate whether self-replicating mRNA (repRNA) can successfully express an endolysin targeting vancomycin-resistant Enterococcus faecium (VRE), and...

This $298,045 Project Grant award from the National Institutes of Health's National Center for Advancing Translational Sciences (CFDA 93.350) aims to establish and develop a high-throughput screening (HTS) assay to identify novel bacterial DNA gyrase poisoning inhibitors. The key products and services to be delivered under this one-year award include: Developing a unique HTS assay to rapidly discover bacterial DNA gyrase poisoning inhibitors from small molecule libraries. This assay will...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $474,363.00 to Rowan University to develop novel antimicrobial peptides inspired by the clinically approved compound daptomycin. The goal is to create new peptide molecules that mimic daptomycin's key mechanisms of action, such as calcium binding and lipid membrane disruption, while improving resistance to...

This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $295,247 will support the development of an innovative medical technology for localized and sustained antibiotic treatment of periprosthetic joint infection. Specifically, the awardee Reselute will design, develop, and validate a proof of concept for an orthopedic spacer implant with a novel porous medium capable of controlled antibiotic elution over 180 days. The implantable...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,995 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Xiretsa Inc., a minority-owned small business located in Santa Barbara, CA. The grant will fund the development of a novel class of antimicrobial compounds called Anti-Infective Conjugated Electrolytes (ACEs) that target the bacterial cell membrane to address the growing threat of antimicrobial resistance. The project...

The National Science Foundation (NSF) awarded a $305,000 SBIR Phase I Project Grant to Giant Biosystems Inc. on March 1, 2025. The project aims to develop a rapid, point-of-care antimicrobial susceptibility testing (AST) kit that can provide results on the same day a sample is taken. This is expected to help physicians utilize the most effective antibiotics sooner, reducing antimicrobial resistance and associated economic burdens. The proposed microfluidic platform is designed to generate...

This $991,832 Cooperative Agreement awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a novel rapid antibiotic susceptibility testing (AST) platform by Astek Diagnostics Inc., a minority-owned small business in Halethorpe, Maryland. The project aims to adapt the company's previously developed urine cartridge technology for use with cerebrospinal fluid and wound effluent specimens, characterize...